ライフサイエンスコーパス: 1,25-dihydroxyvitamin D

1 one (PTH), insulin-like growth factor 1, and 1,25-dihydroxyvitamin D.

2 y low but is highly induced by its substrate 1,25-dihydroxyvitamin D.

3 ne that catabolizes 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D.

4 ceptors (VDRs), suggesting responsiveness to 1,25-dihydroxyvitamin D.

5 not affected by different concentrations of 1,25-dihydroxyvitamin D.

6 emia and inappropriately low serum levels of 1,25-dihydroxyvitamin D.

7 n of 25-hydroxyvitamin D to its active form, 1,25-dihydroxyvitamin D.

8 xyvitamin D and the active vitamin D hormone 1, 25-dihydroxyvitamin D.

9 onstrated potent renoprotective activity for 1,25-dihydroxyvitamin D (1,25(OH)(2)D(3)).

10 The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)(2)D) enhances innate i

11 The product of this enzyme, 1,25-dihydroxyvitamin D (1,25(OH)(2)D), promotes the dif

12 oth plasma 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D) biomarkers.

13 ion induced by the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D) with subsequent RNA

14 etween yearly 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)2D), and FGF23 serum le

15 (PTH) levels (2 degrees HPT), deficiency of 1,25-dihydroxyvitamin D (1,25(OH)2D), and hypocalciuria.

16 , we measured 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)2D), FGF23, and parathy

17 Synthesis of the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25-(OH)(2)D), by renal epithe

18 ciations between serum levels of 25(OH)D and 1,25-dihydroxyvitamin D (1,25[OH](2)D) at baseline and t

19 tients with SS asthma were preincubated with 1,25-dihydroxyvitamin D (1,25[OH]2D [VitD]), followed by

20 in levels of 25-hydroxyvitamin D (25[OH]D), 1,25-dihydroxyvitamin D (1,25[OH]2D), parathyroid hormon

21 1,25-dihydroxyvitamin D (1,25[OH]2D3) modulates innate i

22 dies and mathematical modeling that hormonal 1,25-dihydroxyvitamin D (1,25D) and the vitamin D recept

23 N-gamma) and the calcitropic steroid hormone 1,25-dihydroxyvitamin D (1,25D) are activators of macrop

24 amin D, is converted into the active hormone 1,25-dihydroxyvitamin D (1,25D) by the cytochrome P450 e

25 Here, we show that hormonal 1,25-dihydroxyvitamin D (1,25D) is a direct transcriptio

26 ere relatively insensitive to treatment with 1,25-dihydroxyvitamin D (1,25D), the active form of vita

27 ting in synthesis of the pleiotropic hormone 1,25-dihydroxyvitamin D (1,25VD), which regulates over 6

28 tary fat intake (r = 0.29, P = 0.001), serum 1,25 dihydroxyvitamin D [1,25(OH)(2)D] concentrations (r

29 entrations of 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1, 25(OH)(2)D], intact parathyr

30 Serum concentrations of 1,25-dihydroxyvitamin D [1,25(OH)(2)D] and parathyroid h

31 iciency is related to serum 25(OH)D or serum 1,25-dihydroxyvitamin D [1,25(OH)(2)D] concentrations.

32 endent phosphate transport and production of 1,25-dihydroxyvitamin D [1,25(OH)(2)D] in the proximal t

33 1,25-dihydroxyvitamin D [1,25(OH)(2)D] levels were low i

34 25(OH)D and 1,25-dihydroxyvitamin D [1,25(OH)(2)D] levels were measu

35 Maternal 25(OH)D, parathyroid hormone, and 1,25-dihydroxyvitamin D [1,25(OH)(2)D] were determined a

36 nd serum calcium, parathyroid hormone (PTH), 1,25-dihydroxyvitamin D [1,25(OH)(2)D], 24,25-dihydroxyv

37 entrations of 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)(2)D], and parathyroid

38 e circulating 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)(2)D], and their determ

39 able calcium pool, VO+, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D [1,25(OH)(2)D], parathyroid horm

40 Within monocytes, 1,25-dihydroxyvitamin D [1,25(OH)2D] is important for pr

41 Free 25(OH)D and 1,25-dihydroxyvitamin D [1,25(OH)2D] were lower in obese

42 al VDR, serum 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)2D], and parathyroid ho

43 s, namely, 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)2D], have received the

44 D, genetic disorders of its bioactivation to 1,25-dihydroxyvitamin D [1,25(OH)2D], or disorders of vi

45 tamin D metabolism and inhibit production of 1,25-dihydroxyvitamin D [1,25(OH)2D], the active vitamin

46 25(OH)D is activated in the kidneys to 1,25-dihydroxyvitamin D [1,25(OH)2D], which regulates ca

47 of phosphate (inorganic phosphorus, Pi) and 1,25-dihydroxyvitamin D [1,25(OH)2D].

48 c mice with losartan or paricalcitol (19-nor-1,25-dihydroxyvitamin D(2), an activated vitamin D analo

49 rmone-related peptide, prolactin, estradiol, 1,25-dihydroxyvitamin D, 24-hydroxyvitamin D, femoral bo

50 the hypothesis that calciotrophic hormones [1,25-dihydroxyvitamin D, 25-hydroxyvitamin D, and parath

51 1,25-Dihydroxyvitamin D, 25-hydroxyvitamin D, PTH, femor

52 The vitamin D receptor (VDR) ligand, 1,25 dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), reduces pr

53 own that the active metabolite of vitamin D, 1,25 dihydroxyvitamin D(3), stimulates differentiation a

54 In the present study we report that 1,25-dihydroxyvitamin D(3) (1,25(OH)(2) VD)(3)induces OC

55 se (HG, 25 mm) in the presence or absence of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) (25, 50 nm)

56 Given the immunosuppressive role of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) and its cli

57 that the fat-soluble vitamin D(3) metabolite 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) and its nuc

58 The present study shows that 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) arrests ova

59 keletal metabolism by inducing resistance to 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) by a mechan

60 1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) can modulat

61 We have shown that 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) down-regula

62 The synthesis of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) from its pr

63 o its calciotropic function, the secosteroid 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) has potent

64 The 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) hormone bin

65 ropic effects, the active form of vitamin D, 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is a potent

66 1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is a potent

67 Monocyte differentiation induced by 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is interrup

68 1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) is the biol

69 1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) or Runx2 st

70 1,25-Dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) stimulates

71 n important role in the maintenance of serum 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) under normo

72 CYP24A1 expression is up-regulated by 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) via a vitam

73 The active metabolite of vitamin D (1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3))) is known t

74 The active metabolite of vitamin D, 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), and a seri

75 resistance to the active form of vitamin D [1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3))] who presen

76 ike multinucleated cell formation induced by 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) and parath

77 pothesis that the sunlight-dependent hormone 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) is a natur

78 synthesis, we proposed that vitamin D(3) and 1,25-dihydroxyvitamin D(3) (1,25-(OH)(2)D(3)) may protec

79 Osteoclast formation, whether stimulated by 1,25-dihydroxyvitamin D(3) (1,25-D) or by parathyroid ho

80 It was found that administration of 1,25-dihydroxyvitamin D(3) (1,25[OH](2)D(3)) to mice rap

81 differentiate to monocytes by an exposure to 1,25-dihydroxyvitamin D(3) (1,25D(3)), form a complex, a

82 AAT/enhancer-binding protein (C/EBP) beta in 1,25-dihydroxyvitamin D(3) (1,25D(3))-induced monocytic

83 activated with the active vitamin D hormone 1,25-dihydroxyvitamin D(3) (1,25D(3)).

84 1,25-Dihydroxyvitamin D(3) (1,25D) used to treat human a

85 n active ligand of vitamin D receptor (VDR), 1,25-dihydroxyvitamin D(3) (1,25D3), ameliorated experim

86 Hormonally active vitamin D(3)-1,25-dihydroxyvitamin D(3) (1,25D3)-acts as a signaling

87 ere additive with that of melatonin whereas, 1,25-dihydroxyvitamin D(3) (IC(50)=10 nM), which by itse

88 that naturally recognizes the small molecule 1,25-dihydroxyvitamin D(3) (vit D).

89 oups were cultured in vitamin D-deficient or 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] -supplement

90 vestigated mechanisms by which genistein and 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] act synergi

91 is regulated by two major calcemic hormones, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] and parathy

92 1,25-Dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] induces the

93 Transcriptional regulation by hormonal 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] involves oc

94 1,25-Dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] is a princi

95 the 25-hydroxyvitamin D(3)-24-hydroxylase by 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] is well est

96 In wild-type mice, inhibition of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] synthesis a

97 te cancer risk by lowering concentrations of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], a hormone

98 The active form of vitamin D, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], has a dire

99 1,25-Dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], the active

100 tor that mediates the actions of its ligand, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], which can

101 e for mediating the biological activities of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)].

102 in the spinal cord, so the locally-produced 1,25-dihydroxyvitamin D(3) accumulated and resolved the

103 CaT1 mRNA levels are not responsive to 1,25-dihydroxyvitamin D(3) administration or to calcium

104 D(3)-fed female mice had significantly more 1,25-dihydroxyvitamin D(3) and fewer CYP24A1 transcripts

105 The vitamin D receptor (VDR) binds 1,25-dihydroxyvitamin D(3) and mediates its actions on g

106 data provide the first in vivo evidence that 1,25-dihydroxyvitamin D(3) and the VDR impact on ductal

107 1,25-Dihydroxyvitamin D(3) differentiation of MM6 cells

108 COS-1 cells with the Src-specific activator 1,25-dihydroxyvitamin D(3) enhanced activity; treatment

109 The bone-specific activation and 1,25-dihydroxyvitamin D(3) enhancement of osteocalcin (O

110 esearch has shown a strong protective effect 1,25-dihydroxyvitamin D(3) in experimental autoimmune en

111 nd TRPV6 null mice responded equally well to 1,25-dihydroxyvitamin D(3) in increasing intestinal calc

112 he vitamin D(3) receptor (VDR), whose ligand 1,25-dihydroxyvitamin D(3) is the biologically active fo

113 Serum calcium and 1,25-dihydroxyvitamin D(3) levels were normal but parath

114 ked reductions in 25-hydroxyvitamin D(3) and 1,25-dihydroxyvitamin D(3) levels, despite upregulation

115 The results also suggest that 1,25-dihydroxyvitamin D(3) may not play a role in this a

116 Finally, stimulation of Lyn expression by 1,25-dihydroxyvitamin D(3) treatment in HL-60 cells, a c

117 The responsiveness of RANKL to 1,25-dihydroxyvitamin D(3) was not elevated in the oster

118 e the antiangiogenic activity of calcitriol (1,25-dihydroxyvitamin D(3)) in vivo and its effect on re

119 Oral calcitriol (1,25-dihydroxyvitamin D(3)) prevented as well as partly

120 Although vitamin D hormone (VDH; 1,25-dihydroxyvitamin D(3)), the active metabolite of vi

121 y of CYP3A4, whose expression was induced by 1,25-dihydroxyvitamin D(3), and of CYP1A1, induced by be

122 growth-inhibited by all-trans-retinoic acid, 1,25-dihydroxyvitamin D(3), and transforming growth fact

123 ing in mouse marrow cultures stimulated with 1,25-dihydroxyvitamin D(3), as well as markers of osteoc

124 n circulating levels of parathyroid hormone, 1,25-dihydroxyvitamin D(3), or fibroblast growth factor

125 and fewer CYP24A1 transcripts, encoding the 1,25-dihydroxyvitamin D(3)-inactivating enzyme, in the s

126 ctive 25-dihydroxyvitamin D(3) to the active 1,25-dihydroxyvitamin D(3).

127 l ligand for the vitamin D receptor (VDR) is 1,25-dihydroxyvitamin D(3).

128 full stimulation of RANKL by oncostatin M or 1,25-dihydroxyvitamin D(3).

129 response to the pro-osteoclastogenic factor 1,25-dihydroxyvitamin D(3).

130 s induced to differentiate by an exposure to 1,25-dihydroxyvitamin D(3); however, its activator in th

131 VDRR: 25-hydroxyvitamin D 34 ng/mL (20-100); 1,25-dihydroxyvitamin D 507 pg/mL.

132 f prostate cancer through reduction of serum 1,25-dihydroxyvitamin D, a potent anti-prostate cancer h

133 The active vitamin D metabolite, 1,25-dihydroxyvitamin D, acting through the vitamin D re

134 irculating levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, alopecia persisted in the VDR-n

135 hat encodes the primary catabolic enzyme for 1,25-dihydroxyvitamin D and 25-dihydroxyvitamin D.

136 showed significantly higher serum levels of 1,25-dihydroxyvitamin D and developed extensive calcific

137 , hyperaldosteronism, and elevated levels of 1,25-dihydroxyvitamin D and Fgf23, consistent with disru

138 We assessed 1,25-dihydroxyvitamin D and other biochemical parameters

139 ke growth factor binding protein 3 but lower 1,25-dihydroxyvitamin D and parathyroid hormone concentr

140 ients, older patients had consistently lower 1,25-dihydroxyvitamin D and phosphate levels (p = .013 a

141 ient cardiac surgery-related fluctuations in 1,25-dihydroxyvitamin D and the aforementioned parameter

142 Exogenous calcitriol (1,25-dihydroxyvitamin D) and high circulating levels of

143 PTH, 1,25-dihydroxyvitamin D, and 25-hydroxyvitamin D concent

144 PTH, 1,25-dihydroxyvitamin D, and 25-hydroxyvitamin D concent

145 ns of change in calciotrophic hormones (PTH, 1,25-dihydroxyvitamin D, and 25-hydroxyvitamin D) in the

146 renal 1-alpha-hydroxylase expression, serum 1,25-dihydroxyvitamin D, and calcium levels than KL(fl/f

147 by hypophosphatemia, decreased production of 1,25-dihydroxyvitamin D, and rickets/osteomalacia.

148 blastic conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D appears to be an important posit

149 The biological actions of 1, 25-dihydroxyvitamin D, are mediated through the vitam

150 e concomitant with increased serum levels of 1,25-dihydroxyvitamin-D, as also observed in the Fgf23(-

151 hepcidin gene (HAMP) expression mediated by 1,25-dihydroxyvitamin D binding to the vitamin D recepto

152 We investigated whether administration of 1,25-dihydroxyvitamin D (calcitriol) to critically ill p

153 suggests that autocrine/paracrine actions of 1,25-dihydroxyvitamin D complement the classic endocrine

154 lase for de novo synthesis of a focally high 1,25-dihydroxyvitamin D concentration in the peripheral

155 For those with low serum 1,25-dihydroxyvitamin D concentrations (< or =23 pg per

156 Circulating 1,25-dihydroxyvitamin D concentrations among participant

157 baseline and 18 mo postparturition, PTH and 1,25-dihydroxyvitamin D concentrations did not decline,

158 ) but were not significantly correlated with 1,25-dihydroxyvitamin D concentrations.

159 ith prohormone 25-hydroxyvitamin D or active 1,25-dihydroxyvitamin D decreased expression of hepcidin

160 pro- and antiinflammatory cytokine balance, 1,25-dihydroxyvitamin D failed to improve survival.

161 ate 25-hydroxyvitamin D must be converted to 1,25-dihydroxyvitamin D for full biological activity, an

162 king elevations in serum PTH and calcitriol [1,25-dihydroxyvitamin D] in subjects consuming the low-p

163 oid hormone, but administration of exogenous 1,25-dihydroxyvitamin D increased FGF23 levels.

164 lopecia was not secondary to toxic levels of 1,25-dihydroxyvitamin D interacting with an alternative

165 gate whether the markedly elevated levels of 1,25-dihydroxyvitamin D led to the alopecia, we raised V

166 tabolism was normalized in KO/TG mice: serum 1,25 dihydroxyvitamin D levels were higher in KO/TG mice

167 t with hypercalciuria due to increased serum 1,25-dihydroxyvitamin D levels and increased intestinal

168 n with prediagnostic circulating 25(OH)D and 1,25-dihydroxyvitamin D levels and with two VDR single n

169 Low 1,25-dihydroxyvitamin D levels are associated with infla

170 Hyperphosphatemia and low 1,25-dihydroxyvitamin D levels are associated with morta

171 mine whether therapies aimed at treating low 1,25-dihydroxyvitamin D levels can improve the outcome i

172 for atherosclerosis, parathyroid hormone, or 1,25-dihydroxyvitamin D levels did not alter these assoc

173 Circulating 1,25-dihydroxyvitamin D levels fluctuate in relation to

174 calcium and parathyroid hormone levels, but 1,25-dihydroxyvitamin D levels that are inappropriately

175 ance for dietary magnesium intake, and serum 1,25-dihydroxyvitamin D levels was able to accurately se

176 (+/- SD) serum total 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels were 17 +/- 8 ng/mL and 3

177 The 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels were significantly higher

178 menstruation, estradiol levels, PTH levels, 1,25-dihydroxyvitamin D levels, dietary calcium intake,

179 h mild hypophosphatemia and/or elevations in 1,25-dihydroxyvitamin D levels.

180 ve TaqI genotype (P = 0.005) and circulating 1,25-dihydroxyvitamin-D levels (P = 0.03) as independent

181 tal calcium, phosphate, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, magnesium, and markers of bone

182 stimulatory effect of 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D on related antibacterial protein

183 7.7% (SE: 3.7%) for each pmol/L increment in 1,25-dihydroxyvitamin D (p = .037).

184 , alkaline phosphatase, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, parathyroid hormone, osteocalci

185 Treatment of neonatal cardiomyocytes with 1,25-dihydroxyvitamin D partially reduced isoproterenol-

186 In addition, studies showed that 1,25-dihydroxyvitamin D rapidly activates signal transdu

187 tive form of vitamin D, and cause hereditary 1,25-dihydroxyvitamin D resistant rickets (HVDRR).

188 by hyperphosphatemia, elevated production of 1,25-dihydroxyvitamin D, soft tissue calcifications, and

189 In culture, 1,25-dihydroxyvitamin D suppressed high-glucose-induced

190 f phosphate and inhibits renal production of 1,25-dihydroxyvitamin D, thus helping to mitigate hyperp

191 se converts 25-hydroxyvitamin D [25(OH)D] to 1,25-dihydroxyvitamin D to regulate local innate immune

192 1,25 dihydroxyvitamin D (VD) has been shown to exert a n

193 Circulating 1,25-dihydroxyvitamin D was directly related to glomerul

194 The clinical effectiveness of 1,25-dihydroxyvitamin D was reported in a double-blind,

195 Serum levels of PTH and 1, 25-dihydroxyvitamin D were substantially increased ab

196 culated bioavailable 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D were 2.5 +/- 2.0 ng/mL and 6.6 +